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DRUG EVALUATION
Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the
treatment of non-muscle invasive bladder cancer
R. M. Phillipsa,b, H. R. Hendriksc, J. B. Sweeneya,b, G. Reddyd and G. J. Peterse
aDepartment of Pharmacy, University of Huddersfield, Huddersfield, UK; bDepartment of Chemical Sciences, University of Huddersfield, UK;
cHendriks Pharmaceutical Consulting, Purmerend, The Netherlands; dSpectrum Pharmaceuticals Inc, Irvine, CA, USA; eDepartment of Medical
Oncology, VU University Medical Center, Amsterdam, The Netherlands
ABSTRACT
Introduction: Apaziquone (also known as EO9 and QapzolaTM) is a prodrug that is activated to DNA
damaging species by oxidoreductases (particularly NQO1) and has the ability to kill aerobic and/or
hypoxic cancer cells.
Areas covered: Whilst its poor pharmacokinetic properties contributed to its failure in phase II clinical
trials when administered intravenously, these properties were ideal for loco-regional therapies.
Apaziquone demonstrated good anti-cancer activity against non-muscle invasive bladder cancer
(NMIBC) when administered intravesically to marker lesions and was well tolerated with no systemic
side effects. However, phase III clinical trials did not reach statistical significance for the primary
endpoint of 2-year recurrence in apaziquone over placebo although improvements were observed.
Post-hoc analysis of the combined study data did indicate a significant benefit for patients treated with
apaziquone, especially when the instillation of apaziquone was given 30 min or more after surgery. A
further phase III study is ongoing to test the hypotheses generated in the unsuccessful phase III studies
conducted to date.
Expert opinion: Because of its specific pharmacological properties, Apaziquone is excellently suited for
local therapy such as NMIBC. Future studies should include proper biomarkers.
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1. Introduction
Apaziquone, originally known as EO9 (3-hydroxy-5-aziridinyl-1-
methyl-2-(1H-indole-4,7-dione)prop-β-en-α-ol), was first
synthesized at the University of Amsterdam in 1987 [1]. It
was developed as one of a series of derivatives of mitomycin
C in a program of work sponsored by the Dutch Cancer
Society. Its preclinical evaluation was coordinated by the
New Drug Development Office of the European Organisation
for the Research and Treatment of Cancer (EORTC) in
Amsterdam and involved a number of laboratories belonging
to the Screening and Pharmacology Group and Pharmacology
and Molecular Mechanism groups across Europe [2].
Apaziquone belongs to a class of anticancer drugs known as
bioreductive drugs which are prodrugs designed to be acti-
vated by enzymes (oxidoreductases) present within the tumor
[3]. Depending on the enzymology of individual tumors, it also
has the ability to target hypoxic cells and in this context, it
also functions as a hypoxia-activated prodrug [3,4].
Apaziquone has had a chequered history in that it failed to
show antitumor activity in the clinic following intravenous
administration. One key reason for its failure was poor drug
delivery to tumors caused by its poor systemic pharmacoki-
netic properties in conjunction with poor penetration through
avascular tissue [5]. Paradoxically, these poor pharmacological
properties are beneficial for locoregional therapy and the
rationale for testing apaziquone against non-muscle invasive
bladder cancer (NMIBC) was generated. The pharmacology of
apaziquone has been extensively reviewed elsewhere [6] and
the purpose of this article is to (i) to summarize the clinical
studies where apaziquone was administered intravenously
with the aim of putting its history into an appropriate context
and (ii) to focus on the pharmacology, toxicity, and clinical
activity of apaziquone against NMIBC.
2. Overview of NMIBC and available therapies
Bladder cancer is the ninth most common cancer worldwide
with 429,800 new cases diagnosed in 2012 [7,8]. In the USA, it
is the fourth most common cancer in males with an estimated
76,960 new cases of bladder cancer (both sexes) diagnosed in
2016 and 16,390 deaths [9]. Similarly, it is the fourth most
common cancer in Europe with an estimated 151,252 cases in
2012 (both sexes) and 52,411 deaths [10]. The majority of
these cases (70–75%) present as NMIBC that are defined as
papillary tumors (low and high grade) confined to the mucosa
and invading the lamina propria (stage Ta and T1 respectively)
and includes high grade, flat tumors confined to the mucosa
(carcinoma in situ [CIS] or Tis) [11]. Treatment of NMIBC
(including high-risk G3 and CIS) typically involves surgical
removal by transurethral resection of bladder tumors
(TURBT), but NMIBC has a tendency to recur after TURBT
alone. Adjuvant intravesical instillation of chemotherapy or
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immunotherapy has been shown to reduce tumor recurrence
rates and prevent disease progression [12]. Commonly used
chemotherapeutic drugs for G1/G2 and Ta/T1 tumors include
mitomycin C, valrubicin, epirubicin, cisplatin, and doxorubicin
and European Association of Urology (EAU) and American
Urological Association guidelines recommend single, immedi-
ate post-TURBT intravesical instillation for low- and intermedi-
ate-risk NMIBC [13,14]. Meta-analysis data have shown that
this treatment reduces recurrence rates by 11.7–13.0% com-
pared to TURBT alone [15–17]. In the USA, four agents have
been approved by the FDA for use in NMIBC; ThioTEPA in
1959, Bacillus Calmette-Guérin (BCG) Tice in 1989, BCG
Connaught in1990, and valrubicin in 1998 [18]. ThioTEPA is
no longer widely used because of toxicity issues and mitomy-
cin C is commonly used off-label as an intravesical treatment
for NMIBC. The use of mitomycin C is also associated with rare
but severe toxicities [19–22]. Intravesical immunotherapy with
BCG has been widely used since the 1970s and is frontline
treatment for patients presenting with high-risk lesions (G3
and CIS) and is not administered immediately after surgery
[23,24]. Apaziquone has been evaluated against low-risk (G1/
G2 and Ta/T1) tumors.
Despite adjuvant intravesical therapy, recurrence rates
remain high (30–70%) and EAU and AUA guidelines recom-
mend frequent cystoscopic and cytologic surveillance that
continues for the lifetime of the patient. Recurrence of the
disease together with the cost of intensive surveillance strate-
gies contributes to the high cost of treating this disease [25].
Some authors have stated that bladder cancer has the highest
lifetime treatment costs per patient of all cancers due to the
high recurrence rate and sustained invasive monitoring
requirements [26]. There is therefore a strong pharmacoeco-
nomic need for new therapies that can delay recurrence rates
in NMIBC. In addition, the relative lack of approved treatment
options for NMIBC and the fact that no new therapies have
been approved for NMIBC in the twenty-first century
graphically illustrates the need to develop new drugs for the
management of NMIBC [18]. Finally, NMIBC is a nonlethal
disease and as most patients are old with other comorbid
conditions such as cardiovascular and pulmonary diseases
[27,28], the safety of drugs used after TURBT is also of para-
mount importance. The toxicity profile of novel therapeutics is
also therefore an important consideration in the management
of these patients.
3. Introduction to apaziquone
Apaziquone was originally developed at the University of
Amsterdam in a research project sponsored by the Dutch
Cancer Society (Box 1). The original patent was published in
1987 (WO87/06227) and maintained by the University of
Amsterdam until Kyowa Hakko licensed the compound in
1994 [29]. Kyowa Hakko released the license in 1997/98 and
the patent was maintained by the NDDO Oncology BV and INC
Research. Spectrum Pharmaceuticals (Irvine, California) in-
licensed exclusive worldwide rights to EO9 (currently branded
as Qapzola) from INC Research in 2001. Formulations designed
specifically for the intravesical administration of apaziquone
were developed [30,31] and patented in 2007
(WO2007092964). These formulations led to greater stability
of apaziquone in human urine [32]. In 2008, Spectrum
Pharmaceuticals and Allergan signed an exclusive collabora-
tion for the development and commercialization of EO9 (apa-
ziquone) but Spectrum Pharmaceuticals subsequently
regained exclusive rights to apaziquone in 2013.
3.1. Chemistry
The original synthesis of apaziquone (EO9) was reported in
1987 [1] and since then various methodologies have been
described [33–35] including large-scale synthesis methods
[36,37]. Whilst apaziquone is structurally related to mitomycin
C, its mechanism of action is very different particularly with
respect to NQO1 activation (see below in Section 3.2). The
chemical structure of EO9 is presented in Figure 1. It is an
indolequinone that has three active centers (i) an aziridinyl
group at C5, (ii) a vinylic group at C2, and (iii) the hydroxy-
methyl group at C3. The mechanism(s) of action are presented
in Figures 1 and 2 and these include the generation of reactive
oxygen species via redox cycling [38] (Figure 1) and alkylation
reactions via (i) enzymatic reduction and (ii) proton assisted
aziridine ring opening (Figure 2).
3.2. Mechanism of action and pharmacodynamics
The mechanism of action of apaziquone is complex and has
been extensively reviewed elsewhere [6]. Briefly, the pharma-
codynamics properties of apaziquone can be segregated into
(i) factors that influence the bioreductive activation process
and (ii) how cells respond to the type and extent of DNA
damage induced following bioreductive activation. Several
factors influence the bioreductive activation process and cell
kill is determined by a complex interaction between the
expression of one and two electron oxidoreductases in cells,
the presence or absence of oxygen, and extracellular pH (pHe).
Box 1. Drug summary box: apaziquone
Drug names:
Apaziquone: Apaziquonum; NSC-382459; NOR-701; EOquin; EO 9
(pharmaceutical)
Drug description:
Apaziquone is an indolequinone bioreductive prodrug which is
activated by oxidoreductases (NQO1) to DNA damaging
species which can kill cancer cells6
Formula: C15H16N2O4
Chemical structure:
3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-
en-alpha-ol
IUPAC name:
5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-
methylindole-4,7-dione
Molecular weight: 288.303 g/mol
PubChem CID: 5813717
784 R. M. PHILLIPS ET AL.
D
ow
nl
oa
de
d 
by
 [C
om
pu
tin
g &
 L
ibr
ary
 Se
rv
ice
s, 
Un
ive
rsi
ty 
of
 H
ud
de
rsf
iel
d]
 at
 07
:04
 26
 Se
pte
mb
er 
20
17
 
Several oxidoreductases are capable of reducing apaziquone
but the major ones are the two-electron reductase NAD(P)H:
quinone oxidoreductase 1 (NQO1, also known as DT-diaphor-
ase) and a series of one-electron reductases including cyto-
chrome P450 reductase [6]. Reduction of apaziquone by
purified NQO1 and cytochrome P450 reductase leads to free
radical generation and DNA-damaging species in cell-free
assays [38–40] (Figures 1 and 2). The types of DNA damage
observed in cell-free assays include interstrand cross-links,
mono-adducts, and strand breaks [39,41–43]. With regards to
the induction of DNA cross-links, there are some discrepancies
in the literature with some studies reporting cross-linking
[41,42], whereas others report no cross-link induction follow-
ing reduction of apaziquone by NQO1 in cell-free assays [43].
Species-dependent differences (rat vs. human NQO1) may
account for these differences but similar conflicting results
were reported following the analysis of DNA interstrand
cross-link induction in human cancer cells using alkaline elu-
tion or comet assay techniques [41,44]. Whilst the extent of
DNA interstrand cross-link induction maybe uncertain, it is
clear that apaziquone is reduced by one- and/or two-electron
reductases to species that are capable of damaging DNA by
free radical generation and alkylation.
In addition to the presence of oxidoreductases, the oxyge-
nation state of cells has a significant bearing on the pharma-
codynamic response. In the presence of oxygen, apaziquone is
reduced predominantly by the two-electron reductase NQO1
and several studies have demonstrated that IC50 values are
typically inversely proportional to NQO1 activity [45–48]. In
the absence of oxygen however, significant potentiation of
apaziquone activity is only seen in cells that have low or no
NQO1 activity [47,49], particularly those that harbor the C609T
polymorphic variant of NQO1 [49,50]. In cells with low or no
NQO1, one-electron reductases assume a prominent role
under these conditions, reduction of apaziquone is oxygen
sensitive with the semiquinone rapidly redox cycling back to
the parent compound resulting in the production of reactive
oxygen species (Figure 1). When oxygen is low or absent, the
half-life of the semiquinone increases providing more time to
either alkylate DNA directly or be reduced further to produce
the hydroquinone [51]. The experimental evidence in vitro
clearly indicates that the activity of apaziquone is strongly
dependent upon NQO1 activity and cause cell death in an
oxygen independent manner but in cells that are devoid of
NQO1 activity, apaziquone is able to selectively target hypoxic
cells. The response of tumors in vivo could however not be
predicted based on NQO1 activity [52], but it is likely that poor
systemic pharmacokinetics and penetration through avascular
tissue compromised drug delivery resulting in suboptimal
levels of apaziquone in tumors [5]. This suboptimal accumula-
tion of apaziquone in tumors is possibly sufficient to exert a
radiosensitizing effect. The ability to target hypoxic cells sug-
gests that combination therapy with radiotherapy could be
effective and this was indeed demonstrated in three syngeneic
rat lung cancer models and a rhabdomyosarcoma in vivo
(Table 1) [53], but this strategy was never considered as a
clinical strategy.
The activity of apaziquone is strongly influenced by pHe.
Under mild acidic extracellular conditions (pH 6.0), the cyto-
toxic potency of indolequinones containing aziridine ring
Apaziquone
Semiquinone
Superoxide
Hydroxyl Radical
Hydrogen
peroxide
Figure 1. Redox reactions and generation of reactive oxygen species following the reduction of apaziquone by one electron oxidoreductases. The
quinone nucleus of apaziquone is reduced by NAD(P)H dependent one electron oxidoreductases such as cytochrome P450 reductase to a semiquinone radical which
redox cycles back to the parent quinone in the presence of oxygen generating superoxide anions. Hydrogen peroxide is generated via superoxide dismutase (SOP)
mediated reactions and this in the presence of trace metals can lead to the formation of hydroxyl radicals and subsequent damage to cellular macromolecules.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 785
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functionality (including apaziquone) is significantly enhanced
in vitro [44,54]. The activity of apaziquone remains inversely
proportional to NQO1 activity under acidic pHe conditions,
but potency is significantly enhanced [55]. In contrast to
mitomycin C where reducing the pH increases substrate spe-
cificity and reduction by NQO1 [56], the substrate specificity of
apaziquone for NQO1 is not affected by pH [55]. Whilst the
cytotoxic potency of apaziquone is enhanced under acidic
Figure 2. Mechanisms for DNA alkylation by apaziquone: (i) Pathways involving one- and two-electron reduction. Proton-coupled single-electron reduction
of apaziquione generates stablised radical A, which can be further reduced (via B) to key intermediate C; C can be alkylated via cation D, formed by acid-catalysed
dehydration, to give DNA monoadduct E. can undergo a second dehydration, giving dienyl cation F, which can be trapped in a second DNA alkyation event, giving
interstrand cross-linked species G. (ii) Proton-accelerated mechanism. The conjugation of the aziridinyl lone-pair (acting as a vinylogous amide) into the quinone
ring allows for an addition proton-accelerated DNA alkylation mechanism. Thus, protonation leads to cation A, which is in resonance with B; ring-opening of the
reactive aziridinium moiety of B by DNA leads to aza-quinone species C, which can then undergo reduction to D. Acid-catalysed dehydration of D gives methylene
indolium cation E, which can function as an active alkylating agent.
786 R. M. PHILLIPS ET AL.
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conditions, its chemical stability is decreased resulting in
enhanced formation of EO5A in the absence of cells [54].
These apparently paradoxical properties can be explained by
proton-assisted aziridine ring opening and enhanced nucleo-
philic attack (Figure 2), the outcome of which would vary
depending on the type of nucleophile (e.g. water or DNA)
present in the system.
In summary, the pharmacodynamic properties of apazi-
quone are determined by a complex ‘cocktail’ of parameters
including (i) the presence or absence of NQO1, (ii) the pre-
sence of one-electron reductases such as cytochrome P450
reductase, (iii) the presence or absence of oxygen, (iv) acidic
pHe, and (v) repair of DNA damage. The preclinical data
suggests that apaziquone should (i) target the aerobic and
hypoxic fraction of NQO1 rich tumors equally efficiently, (ii)
target the hypoxic fraction of tumors that have low NQO1
activity, particularly those that harbor the inactivating NQO1
single nucleotide polymorphic variant, and (iii) target cells that
reside in an environment where pHe is mildly acidic. Most of
these parameters are related to the bioreductive activation
process but as stated above, the second important parameter
that determines response is how the cell responds to the
damage induced in terms of detoxification and repair. As
apaziquone can induce strand breaks via the induction of
ROS, antioxidant defense mechanisms could modulate activity
and antioxidants such as catalase and Tempol have been
shown to reduce DNA damage and apaziquone cytotoxicity
[57,58]. Despite the fact that apaziquone has been studied for
30 years, comparatively little is known about the role DNA
repair plays in determining response and further studies are
required to address this issue.
3.3. Pharmacokinetics and metabolism
Full details of preclinical and clinical pharmacokinetics follow-
ing intravenous administration have been reviewed in detail
elsewhere [6]. The suboptimal pharmacokinetic profile of apa-
ziquone is illustrated by the results of phase I studies where
apaziquone is rapidly cleared from the systemic circulation
with half-lives ranging from 0.8 to 19 min [59]. Furthermore,
the predominant metabolite found in blood and urine follow-
ing intravenous administration was the inactive, aziridine ring
open metabolite EO5A [54,59]. Following intravesical adminis-
tration, two clinical studies have investigated the pharmaco-
kinetic and safety of apaziquone [60,61]. In the first of these
studies [61], apaziquone was administered 2 weeks after
TURBT and for the first six patients entered into the trial,
each received an escalating dose of apaziquone with one
dose per week (for a total of 6 weeks). At all doses adminis-
tered, no detectable levels of apaziquone or EO5A were found
in the blood. At the end of the 1-h intravesical instillation, over
60% of the administered dose of apaziquone (but not EO5A)
was recovered from urine, the concentration being propor-
tional to the dose administered [61]. Overall exposure para-
meters within the bladder considerably exceeded plasma AUC
values following intravenous administration indicating that
therapeutically relevant concentrations of drug were delivered
to tumors in the bladder [6,61]. The second study was con-
ducted in a total of 20 patients with NMIBC and a single 4 mg/
40 ml dose of apaziquone was administered intravesically
within 6 h of TURBT [60]. No apaziquone or EO5A were
detected in the blood of patients during and after the instilla-
tion. In acidified urine, a degradation product known as EO-9-
Cl has been reported [31], but the presence of this product
was not observed in clinical studies. Pharmacokinetic studies
following the intravesical administration of apaziquone to
NMIBC patients are therefore limited but in both studies,
high levels of apaziquone (4 mg/40 ml) were delivered into
the bladder but no detectable levels of drug or known meta-
bolites reached the systemic circulation.
3.4. Clinical efficacy
A number of clinical trials were conducted following the intra-
venous administration of apaziquone and details of these are
reviewed elsewhere [6]. This review will focus only on the
clinical trials conducted to date following the intravesical
administration of apaziquone to NMIBC patients. In a phase
I/II pilot study, 12 patients with low-risk NMIBC were adminis-
tered apaziquone intravesically (once a week for 6 weeks; 0.5–
16 mg/40 ml) and antitumor effects were determined against
marker lesions left in the bladder at TURBT [61]. A total of
eight complete responses as defined by both visual loss of the
marker lesion (Figure 3) and pathological confirmation of no
tumor at the marker lesion site was reported. Biomarker stu-
dies were conducted in the phase I/II study using immunohis-
tochemical analysis of NQO1 and Glut-1, the latter being an
Table 1. In vivo antitumor activity of apaziquone (EO9) in combination
with radiation in experimental rat tumors. The tumors were two squamous
cell lung carcinomas (L17 and L42), a lung adenocarcinoma (L27), and a
rhabdomyosarcoma (BA1112). All tumors were grown subcutaneously and EO9
was administered intraperitoneally (daily × 5 at 0.4 mg/kg). When EO9 was
combined with 5 daily doses of 4Gy, additive or synergistic effects were
observed. This data were originally reported by Kal et al [53].
Specific growth delay
Regimen L17 L42 L27 BA1112
EO9 0.1 1.9 1.5 (3.3) 0
EO9 + Enflurane 0.1 2.2 2.6 Not done
5 × 4Gy 1.5 4.4 19.7a (7.4) 5.6
EO9 + 4Gy 2.2 4.6 18a (11.0)b Not done
4Gy + EO9 1.8 3.9 31a (14.5) 7.2
aCure rates: 2/6, 2/3, and 4/5, respectively; bcure rate 1/5; between brackets
results of 5 × 2Gy. Enflurane was used as an inhalational anesthesia for
irradiation of the rats.
Figure 3. The presence of a marker lesion prior to (A) and after (B) a
6 week course of apaziquone. The results were first presented in the review
article by Phillips et al, reproduced with permission [6].
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY 787
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endogenous marker of hypoxia [61]. Whilst a broad range of
NQO1 and Glut-1 protein expression was detected in tumors,
there was no correlation between the response of the marker
lesion and biomarker expression. These studies were only
conducted on 12 patients and no further biomarker studies
were performed in subsequent clinical trials. Because of the
low number of patients, it is advised to include extensive
biomarker studies (focusing on NQO1 and other hypoxia bio-
markers) in future studies. Specific PET imaging probes might
also help to determine rate of hypoxia in tumors.
Using an identical marker lesion study design, 31 out of a
total of 46 patients with multiple pTa or pT1 tumors achieved
a complete response in phase II trials at a dose of 4 mg/40 ml
[62]. Marker lesion studies have been conducted for many
other cytotoxic and immune response modifiers, but the com-
plete response rate achieved by apaziquone (67%) was the
highest reported complete response rate [63]. Two-year fol-
low-up studies demonstrated that long-term results were
good in comparison to other ablative studies with a recur-
rence-free rate of 49.5% at 2 years [64]. Similar results were
reported using patients enrolled on the phase I/II clinical pilot
study [65]. Phase II studies of intravesically administered apa-
ziquone to high-risk NMIBC have also reported encouraging
results [66]. These results were promising, but it is however
acknowledged that the number of phase II studies is limited
and randomized phase III studies are required [67].
Two phase III trials (SPI-611 and 612) were completed and
the results were presented at the American Urological
Association annual meeting in 2016 [68,69]. Both studies had
similar designs and a single dose of apaziquone (4 mg/40 ml)
was administered intravesically to patients with low-risk
NMIBC (TaT1 and G1/G2 lesions) within 6 h of TURBT and
retained for 1 h. The control arm consisted of the administra-
tion of the placebo in both studies. The primary endpoint was
the 2-year recurrence rate and the secondary endpoint was
time to recurrence. Taking both studies together, 1614
patients were enrolled across 152 centers in the USA, Poland,
and Canada (study 612 only). The studies were analyzed indi-
vidually and both did not meet their primary endpoint of a
statistically significant difference in the 2-year recurrence rate
between treatment and placebo arms. When the results of the
two trials were pooled, however, statistically significant differ-
ences were obtained in both the 2-year recurrence rate (apa-
ziquone 38.8% vs. placebo 45.5%; p = 0.0218) and time to
recurrence (apaziquone 18.2 months vs. placebo 16.8 months;
P = 0.0096; Hazard ratio 0.79) [68]. Furthermore, post hoc
analysis of data from both studies demonstrated that a sig-
nificant difference in time to recurrence (Hazard ratio 0.48;
p = 0.0096) was observed in the 117 patients who received
apaziquone >30 min post-TURBT compared to placebo (100
patients). Patients in the apaziquone 31–90 min subgroup also
showed a significant absolute decrease in the 2-year recur-
rence rate (apaziquone 28.2% vs. placebo 50%; p = 0.001)
resulting in a 43.6% relative reduction in 2-year recurrence
rates [69], but no improvements were found in the other 2
subgroups (<30 min, later than 90 min). The result in the
<30 min could be explained by the fact that blood released
during surgery could inactivate apaziquone [70]. Loadman
et al. [70] indeed demonstrated that EO9 is rapidly degraded
by blood in vitro. However, the FDA’s Oncologic Drugs
Advisory Committee recently determined that apaziquone
did not show sufficient statistical evidence of treatment effect
of apaziquone over placebo based on the primary endpoint
results of individual studies and that the post hoc analysis
conducted by Spectrum Pharmaceuticals was hypothesis gen-
erating. The FDA have granted an SPA agreement for a new
phase III study to address the issues arising from SPI-611 and
612, particularly with regards to the timing of apaziquone
administration post-TURBT. Spectrum plans to initiate enrol-
ment in this study.
Preclinical toxicology studies in mice were reported in 1993
and the most obvious finding was a lack of myelosuppression,
a result that was considered unique for what was essentially
an alkylating agent [2]. No myelosuppression was also
reported in the phase I and II studies when EO9 was adminis-
tered intravenously [59,71]. Dose-limiting toxicity in these stu-
dies was reversible proteinuria that was attributed to high
levels of NQO1 found within the kidney. In the phase I/II
study following intravesical administration to patients with
NMIBC, 6 patients received escalating doses of apaziquone
(0.5–16 mg/40 ml) weekly for 6 weeks. A further 6 patients
received weekly apaziquone for 6 weeks at the highest non-
toxic dose (4 mg/40 ml). Grade 2 and 3 dysuria and hematuria
were observed at doses above 8 mg/40 ml, but 4 mg/40 ml
was well tolerated [61]. Apaziquone was also well tolerated in
phase II studies when administered either as 6 weekly infu-
sions at 4 mg/40 ml [62] and as a single dose administered
within 6 h of TURBT [60]. In phase III studies (single dose of
4 mg/40 ml administered within 6 h of TURBT), apaziquone
was well tolerated with a safety profile that was indistinguish-
able from placebo, with a similar incidence of adverse events
(80.0% vs. 78.5%, respectively) with dysuria as the most com-
mon treatment-related adverse event in both the apaziquone
and placebo group 4.6 versus 4.1%, respectively) [68]. Hence,
the safety profile of apaziquone is very good and at 4 mg/
40 ml, apaziquone was well tolerated following both single
and multiple instillations. This compares favorably with other
agents such as the structurally related (but mechanistically
very different) anticancer drug mitomycin C used to treat
NMIBC where rare but severe side effects have been reported
[19–22]. Of course, the occurrence of rare adverse events
caused by apaziquone cannot be ruled out until larger num-
bers of patients have been treated, but the early signs are that
apaziquone has a favorable toxicity profile. In the context of
managing elderly NMIBC patients with comorbidities, the
excellent safety profile of apaziquone is very encouraging.
4. Conclusion
There is a clear need for new therapeutic approaches to
treating NMIBC [18]. From both a pharmacoeconomic and
patient perspective, the development of new therapies that
can delay the recurrence of NMIBC and are well tolerated
would have a significant financial impact on health-care pro-
viders. Apaziquone demonstrated excellent activity against
NMIBC in marker lesion studies, but the clinical improvement
in phase III studies required for drug approval is yet to be
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demonstrated. It is important to state that the design of the
phase III studies was significantly different from the phase I/II
studies. With hindsight, the presence of blood in the bladder
shortly after TURBT should have been considered as inactivat-
ing metabolism of apaziquone by blood [70] and this could
have had a significant bearing on the outcome of these trials.
A further phase III study has been designed and the results of
this trial will be definitive.
5. Expert opinion
Apaziquone was initially developed as a bioreductive drug
designed to target NQO1 rich and/or hypoxic tumors. Initial
clinical studies following intravenous administration failed to
show ant-tumor activity at doses that caused toxicity and it
was not developed further. These early clinical trials did not
include potential biomarkers (e.g. hypoxia, NQO1) or test the
drug in combination with other modalities and it is feasible
that the lack of target expression in the patient’s tumors could
account for its poor efficacy in clinical trials [72]. Moreover, the
drug showed a very unfavorable pharmacokinetic profile lead-
ing to poor drug delivery to tumors and development was
halted, until it was recognized that such a profile would be
ideal for local administration. Any leakage to the systemic
circulation would immediately be taken care of by a rapid
degradation and elimination. Early clinical studies by bladder
instillation showed very promising data with limited local and
no systemic toxicity. Significant activity against marker lesions
in phase I and II studies clearly demonstrates that apaziquone
has anticancer activity, but this failed to translate into positive
results in phase III trials. Whilst the two, randomized phase III
studies failed to reach statistical significance, there was some
evidence from post hoc analysis of pooled results of significant
activity. The FDAs Oncologic Drugs Advisory Committee were
not convinced of the validity of the statistical analysis and a
further phase III trial is required to test the hypotheses gener-
ated from the completed studies. Despite these disappointing
results, it is our opinion that the development of apaziquone
should continue and future studies should take several aspects
into account such as the instability at acidic conditions and
protein binding, as well as timing of the instillation (between
31 and 90 min) after surgery. The stability issue of apaziquone
is taken care off by using a buffered formulation (pH 9.2) for
the drug, which prolonged stability of apaziquone during
instillation, even when mixed with acid urine [31]. Other future
applications of apaziquone would be regional treatment for
other malignancies, even in the prevention setting. Moreover,
apaziquone is an excellent radiosensitizer, which offers possi-
bilities for combinations with radiotherapy, including bladder
cancer, but also other types of localized tumors would be
eligible. From a wider perspective, the developmental history
of this drug shows that compounds with poor pharmacologi-
cal profile are not necessarily precluded from further develop-
ment as loco-regional therapies.
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